Targeted Oncology8 小时
Targeting ESR1 Mutations in Breast Cancer With Novel Therapies
Seth Wander, MD, PhD, discusses approved and upcoming targeted therapies for patients with ESR1-mutated breast cancer.
Targeted Oncology3 天
Understanding the Significance of ESR1 Mutations in Breast Cancer
Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...
MPR3 天
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
来自MSN3 个月
Oral SERD Impresses in Advanced Breast Cancer With ESR1 Mutations
SAN ANTONIO -- Among patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, treatment with imlunestrant did not significantly improve progression-free survival (PFS ...
The Bakersfield Californian15 天
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14. ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and ...